Strensiq (Asfotase alfa)
- Medicine Name: Strensiq
- Generic Name: Asfotase alfa
- Dosage Form & Strength: Injection: 80 mg/0.8 mL, 40 mg/mL, 28 mg/0.7 mL, or 18 mg/0.45 mL solution in single-use vials
- Manufactured By: Alexion Pharmaceuticals, Inc.
Strensiq is a tissue nonspecific alkaline phosphatase and the only prescription medicine used to treat patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
Dosage for Perinatal/Infantile-Onset HPP: The recommended dosage of Strensiq injection for treating perinatal/infantile-onset HPP is 6 mg/kg/weekly given subcutaneously as either 2 mg/kg three (3) times per week, or 1 mg/kg six (6) times per week. Injection site reactions may be responsible for limiting the tolerability of the six (6) times per week dosage regimen.
The dose of Strensiq may be scaled up for lack of efficacy up to 9 mg/kg per week given subcutaneously as 3 mg/kg three (3) times per week.
Dosage for Juvenile-Onset HPP: The recommended dosage of Strensiq for treating juvenile-onset HPP is 6 mg/kg/weekly given subcutaneously as either 2 mg/kg three (3) times weekly, or 1 mg/kg six (6) times weekly. Injection site reactions may be responsible for limiting the tolerability of the six times per week dosage regimen.
Caution: Avoid the use of Strensiq 80 mg/0.8 mL vial in those pediatric patients who weighing below 40 kg because the systemic exposure of asfotase alfa achieved with the Strensiq vial 80 mg/0.8 mL (greater concentration) is below that achieved with the other existing strength vials of Strensiq injection (reduced concentration). A reduced exposure may not be appropriate for this subgroup of patients.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.